Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect additional data on safety and performance of Phasix™ Mesh in subjects requiring Ventral Hernia Working Group (VHWG) Grade 3 midline hernia repair.
Approximately 85 subjects, at approximately 12 sites across Europe will be enrolled and treated to study the use of Phasix™ Mesh. All treated subjects will be followed for 2 years post-implantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phasix™ Mesh | Experimental | Patients treated with Phasix™ Mesh for hernia repair |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Phasix™ Mesh | Device | A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With One or More Surgical Site Occurrence Within 3 Months of Index Procedure | Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes> | 3 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With One or More Surgical Site Occurrence Within 24 Months of Index Procedure | Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes> " |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hans Jeekel | Erasmus University Medical Centre Rotterdam | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wilhelminenspital | Vienna | Austria | ||||
| Imelda Ziekenhuis |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34282506 | Derived | Van Rooijen MMJ, Tollens T, Jorgensen LN, de Vries Reilingh TS, Piessen G, Kockerling F, Miserez M, Windsor ACJ, Berrevoet F, Fortelny RH, Dousset B, Woeste G, van Westreenen HL, Gossetti F, Lange JF, Tetteroo GWM, Koch A, Jeekel J. Slowly resorbable biosynthetic mesh: 2-year results in VHWG grade 3 hernia repair. Hernia. 2022 Feb;26(1):131-138. doi: 10.1007/s10029-021-02453-1. Epub 2021 Jul 19. | |
| 30458747 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study subjects were enrolled between 22-Mar-2016 and 26-Apr-2017 at 15 different sites in 8 European countries.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Phasix™ Mesh | Patients treated with Phasix™ Mesh for hernia repair Phasix™ Mesh: A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB) |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Phasix™ Mesh | Patients treated with Phasix™ Mesh for hernia repair Phasix™ Mesh: A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With One or More Surgical Site Occurrence Within 3 Months of Index Procedure | Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes> | Posted | Count of Participants | Participants | 3 Months |
|
24 months
In this study, an Adverse Event (AE) is defined as any undesirable clinical event occurring in the abdominal space including the lower abdominal, inguinal and pubic regions (including the skin), as well as any other undesirable clinical events judged to be related to the study device or surgical procedure regardless of anatomical region. The definition of Serious AE does not deviate.
Monitors have actively reviewed the subjects' medical records for Adverse Events during monitor visits.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Phasix™ Mesh | Patients treated with Phasix™ Mesh for hernia repair Phasix™ Mesh: A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB) |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Wall Abscess | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sandra van Guldener | Becton, Dickinson and Company | +31 6 46900840 | sandra.vanguldener@bd.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Oct 12, 2018 | May 18, 2020 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 9, 2019 | May 18, 2020 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D006547 | Hernia |
| D046449 | Hernia, Abdominal |
| D000069290 | Incisional Hernia |
| ID | Term |
|---|---|
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 24 Months |
| Number of Participants With a Hernia Recurrence | Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure. | 24 Months |
| Number of Participants With One or More Surgical Site Infection | Proportion of subjects with surgical site infections. Infections at the surgical site will be assessed by physical examination at each study visit through 24 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the US Centers of Disease Control and Prevention (CDC) guidelines for superficial, deep and organ/space surgical site infections. | 24 Months |
| Mean Change in Pain Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure, as Measured by a 10.0 cm Visual Analogue Scale | Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month follow up. Scores are measured on a 10.0 cm line, lower values correspond with low pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up. A negative score means a decrease in pain perception. | 24 Months |
| Number of Participants With One or More Device-related Adverse Event | Incidence Device-related Adverse Events: number of subjects with one or more possibly or definitely device-related Adverse Event. | 24 Months |
| Number of Participants Requiring Reoperation Due to Index Hernia Repair | Rate of reoperation due to the index hernia repair: the proportion of subjects with post-procedure reoperation due to the index hernia repair. | 24 Months |
| Mean Patient Reported Outcomes on Quality of Life Parameters as Measured by the Carolinas Comfort Scale (CCS) at 1, 3, 12 and 24 Months Post-Index Procedure | Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties. Absolute values of the Total CCS Score at 1-Month follow-up, at 3-Month follow-up, at 12-Month follow-up and at 24-Month follow up are reported. The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results. | 24 Months |
| Mean Change in Quality of Life Assessments as Measured by the EQ-5D Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure | Change in self-reported quality of life measured by EuroQol-5 Dimensions (EQ-5D™). Each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) has 3 levels (no problems, some problems and extreme problems). The data is converted into a summary index number between 0 and 1, whereby 1 corresponds with the highest perception of Quality of Life. The outcome measure reports the absolute change from Baseline until 24-months follow up. A positive value corresponds with an increase in Quality of Life. | 24 Months |
| Mean Surgical Procedure Time of the Index Procedure as Measured From Incision to Closure | Surgical procedure time as measured from incision to closure (skin to skin) | 1 day |
| Mean Time Until Participants Were Able to Return to Work | The number of days until subject returned to work, calculated as the date when employed subjects were able to fully get back to work minus the date of surgery. | 24 Months |
| Mean Length of Hospital Stay Related to Index Procedure | The length of hospital stay for the index procedure is calculated as the date of hospital discharge minus the date of hospital admission. Days in intensive care unit, days in step down unit (medium care) and days in the ward will be summarized as well. | 1 Month |
| Bonheiden |
| Belgium |
| UZ Gent | Ghent | Belgium |
| UZ Leuven (Gasthuisberg) | Leuven | Belgium |
| Bispebjerg Hospital | Copenhagen | Denmark |
| Centre Hospitalier Régional Universitaire de Lille | Lille | France |
| APHP Hôpital Cochin | Paris | France |
| Day Surgery and Hernia Center | Cottbus | Brandenburg | Germany |
| Vivantes Hospital | Berlin | Germany |
| Klinikum der Johann Wolfgang Goethe-Universität | Frankfurt | Germany |
| Policlinico Umberto I | Roma | Italy |
| IJsselland Ziekenhuis | Capelle aan den IJssel | Netherlands |
| Elkerliek Ziekenhuis | Helmond | Netherlands |
| Isala | Zwolle | Netherlands |
| University College London Hospitals NHS Trust | London | United Kingdom |
| Derived |
| van Rooijen MMJ, Jairam AP, Tollens T, Jorgensen LN, de Vries Reilingh TS, Piessen G, Kockerling F, Miserez M, Windsor ACJ, Berrevoet F, Fortelny RH, Dousset B, Woeste G, van Westreenen HL, Gossetti F, Lange JF, Tetteroo GWM, Koch A, Kroese LF, Jeekel J. A post-market, prospective, multi-center, single-arm clinical investigation of Phasix mesh for VHWG grade 3 midline incisional hernia repair: a research protocol. BMC Surg. 2018 Nov 20;18(1):104. doi: 10.1186/s12893-018-0439-7. |
| Physician Decision |
|
| Phasix Mesh explanted |
|
| unable due to non-study-related illness |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| BMI | Mean | Standard Deviation | kg/m^2 |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Number of Participants With One or More Surgical Site Occurrence Within 24 Months of Index Procedure | Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes> " | Posted | Count of Participants | Participants | 24 Months |
|
|
|
| Secondary | Number of Participants With a Hernia Recurrence | Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure. | Posted | Count of Participants | Participants | 24 Months |
|
|
|
| Secondary | Number of Participants With One or More Surgical Site Infection | Proportion of subjects with surgical site infections. Infections at the surgical site will be assessed by physical examination at each study visit through 24 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the US Centers of Disease Control and Prevention (CDC) guidelines for superficial, deep and organ/space surgical site infections. | Posted | Count of Participants | Participants | 24 Months |
|
|
|
| Secondary | Mean Change in Pain Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure, as Measured by a 10.0 cm Visual Analogue Scale | Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month follow up. Scores are measured on a 10.0 cm line, lower values correspond with low pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up. A negative score means a decrease in pain perception. | Posted | Mean | Standard Deviation | score on a scale | 24 Months |
|
|
|
| Secondary | Number of Participants With One or More Device-related Adverse Event | Incidence Device-related Adverse Events: number of subjects with one or more possibly or definitely device-related Adverse Event. | Posted | Count of Participants | Participants | 24 Months |
|
|
|
| Secondary | Number of Participants Requiring Reoperation Due to Index Hernia Repair | Rate of reoperation due to the index hernia repair: the proportion of subjects with post-procedure reoperation due to the index hernia repair. | Posted | Count of Participants | Participants | 24 Months |
|
|
|
| Secondary | Mean Patient Reported Outcomes on Quality of Life Parameters as Measured by the Carolinas Comfort Scale (CCS) at 1, 3, 12 and 24 Months Post-Index Procedure | Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties. Absolute values of the Total CCS Score at 1-Month follow-up, at 3-Month follow-up, at 12-Month follow-up and at 24-Month follow up are reported. The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results. | Posted | Mean | Standard Deviation | score on a scale | 24 Months |
|
|
|
| Secondary | Mean Change in Quality of Life Assessments as Measured by the EQ-5D Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure | Change in self-reported quality of life measured by EuroQol-5 Dimensions (EQ-5D™). Each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) has 3 levels (no problems, some problems and extreme problems). The data is converted into a summary index number between 0 and 1, whereby 1 corresponds with the highest perception of Quality of Life. The outcome measure reports the absolute change from Baseline until 24-months follow up. A positive value corresponds with an increase in Quality of Life. | Posted | Mean | Standard Deviation | score on a scale | 24 Months |
|
|
|
| Secondary | Mean Surgical Procedure Time of the Index Procedure as Measured From Incision to Closure | Surgical procedure time as measured from incision to closure (skin to skin) | Posted | Mean | Standard Deviation | minutes | 1 day |
|
|
|
| Secondary | Mean Time Until Participants Were Able to Return to Work | The number of days until subject returned to work, calculated as the date when employed subjects were able to fully get back to work minus the date of surgery. | Of the 84 enrolled subjects, only 26 were employed at the time of the index surgery and of these 23 went back to work. | Posted | Mean | Standard Deviation | days | 24 Months |
|
|
|
| Secondary | Mean Length of Hospital Stay Related to Index Procedure | The length of hospital stay for the index procedure is calculated as the date of hospital discharge minus the date of hospital admission. Days in intensive care unit, days in step down unit (medium care) and days in the ward will be summarized as well. | Posted | Mean | Standard Deviation | days | 1 Month |
|
|
|
| 3 |
| 84 |
| 40 |
| 84 |
| 35 |
| 84 |
| Abdominal Hernia Gangrenous | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Device Related Infection | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Gastroenteritis Viral | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Medical Device Site Infection | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Pelvic Abscess | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Peritonitis | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Post Procedural Pneumonia | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Postoperative Wound Infection | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Cardio-Respiratory Arrest | Cardiac disorders | MedDRA 19.0 | Systematic Assessment |
|
| Mitral Valve Incompetence | Cardiac disorders | MedDRA 19.0 | Systematic Assessment |
|
| Abdominal Fat Apron | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Hiatus Hernia | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Ileus | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Large Intestine Perforation | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Small Intestinal Obstruction | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Anastomotic Fistula | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Gastrointestinal Anastomotic Leak | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Hip Fracture | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Incisional Hernia | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Incisional Hernia, Obstructive | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Postoperative Ileus | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Procedural Intestinal Perforation | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Rectal Laceration Postoperative | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Stomal Hernia | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Subcutaneous Haematoma | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Thoracic Vertebral Fracture | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Wound Dehiscence | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 19.0 | Systematic Assessment |
|
| Fistula | Musculoskeletal and connective tissue disorders | MedDRA 19.0 | Systematic Assessment |
|
| Adenocarcinoma of Colon | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 19.0 | Systematic Assessment |
|
| Endometrial Cancer Recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 19.0 | Systematic Assessment |
|
| Oropharyngeal Cancer Recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 19.0 | Systematic Assessment |
|
| Prostate Cancer Recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 19.0 | Systematic Assessment |
|
| Rectal Adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 19.0 | Systematic Assessment |
|
| Cerebrovascular Insufficiency | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
|
| Acute Kidney Injury | Renal and urinary disorders | MedDRA 19.0 | Systematic Assessment |
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 19.0 | Systematic Assessment |
|
| Ureterolithiasis | Renal and urinary disorders | MedDRA 19.0 | Systematic Assessment |
|
| Urinary Retention | Renal and urinary disorders | MedDRA 19.0 | Systematic Assessment |
|
| Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Pneumonia Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Skin Necrosis | Skin and subcutaneous tissue disorders | MedDRA 19.0 | Systematic Assessment |
|
| Iliac Artery Occlusion | Vascular disorders | MedDRA 19.0 | Systematic Assessment |
|
| Peripheral Artery Occlusion | Vascular disorders | MedDRA 19.0 | Systematic Assessment |
|
| Peripheral Artery Thrombosis | Vascular disorders | MedDRA 19.0 | Systematic Assessment |
|
| Abdominal Wall Haematoma | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
|
| Incisional Hernia | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Postoperative Wound Infection | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
|
| Seroma | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Skin Necrosis | Skin and subcutaneous tissue disorders | MedDRA 19.0 | Systematic Assessment |
|
| Stomal Hernia | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Subcutaneous Haematoma | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
| Wound Dehiscence | Injury, poisoning and procedural complications | MedDRA 19.0 | Systematic Assessment |
|
Not provided
| Title | Measurements |
|---|---|
|
| Total CCS Score at 24-Months |
|
| Title | Measurements |
|---|---|
|
| Days in the Ward |
|